ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Abstract: INFO13-TH

Felzartamab (Anti-CD38 Antibody) for the Treatment of Lupus Nephritis: An Open-Label Phase 1b Study

Session Information

  • Informational Posters - I
    November 02, 2023 | Location: Exhibit Hall, Pennsylvania Convention Center
    Abstract Time: 10:00 AM - 12:00 PM

Category: Glomerular Diseases

  • No subcategory defined

Authors

  • Rovin, Brad H., The Ohio State University, Columbus, Ohio, United States
  • Pineda, Lilia D., Human Immunology Biosciences Inc, South San Francisco, California, United States
  • Patel, Uptal D., Human Immunology Biosciences Inc, South San Francisco, California, United States
  • Tersini, Karen, Human Immunology Biosciences Inc, South San Francisco, California, United States
  • Mysler, Eduardo, Reumatologo en Organization Medica de Investigation (OMI), Buenos Aires, Argentina
  • Dall'Era, Maria, UCSF Medical Center, San Francisco, California, United States
Description

Background: Lupus Nephritis (LN) is an organ-threatening manifestation of SLE with only 30-40% of patients achieving complete renal response with current standard of care. A hallmark of LN is high-titer autoantibodies which are predominantly produced by CD38+ plasma cells. Autoantibodies form immune complexes that deposit in the glomerulus and incite kidney damage via production of inflammatory mediators including Type I interferons (IFN). CD38 expression is also induced on plasmacytoid Dendritic Cells (pDCs), the primary source of Type I IFN. CD38 is thus a compelling target for depletion of pathogenic cells in LN, supported by emerging clinical data that anti-CD38 therapy in LN is well tolerated with evidence of disease improvement or resolution.

Felzartamab (felza) is a fully human, anti-CD38 investigational agent in development for several immune-mediated kidney diseases, including primary membranous nephropathy (PMN), IgA nephropathy, and antibody-mediated kidney transplant rejection. Felza is well tolerated with encouraging evidence of CD38+ cell depletion and lowering autoantibodies. In studies of high-risk PMN pts, felza resulted in rapid, deep, and durable aPLA2R autoantibody responses with associated improvements in proteinuria and serum albumin. A global, open-label Ph1b study testing the safety and efficacy felza in LN is ongoing.

Objective: To generate safety, tolerability, and proof-of-concept data of felza in LN

Methods: ~20 pts in US, Canada, Australia, Argentina, Chile, and Mexico with SLE and Class III or IV +/- V LN will receive 9 IV doses of felza over 5 months with 7 months of follow-up. Key inclusion criteria: (1) UPCR > 1.0 g/g, (2) eGFR ≥ 45 mL/min/1.73 m2, (3) positive anti-dsDNA and/or low complement 3, and (4) history of inadequate response to a minimum 3-month course of standard LN treatment. Primary endpoint is safety and tolerability of felza, and key secondary and exploratory endpoints include pharmacokinetics, efficacy of felza (proteinuria, eGFR, SLEDAI-2K), serologic markers (change in C3 and anti-dsDNA), and other blood and urinary biomarkers (e.g., immune cells,Type I IFN, etc).

Funding

  • Human Immunology Biosciences Inc